Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Health Care

Health Care

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • Earnings
  • General
  • Health Care
  • Large Cap
  • News

Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products

By Vandana Singh
October 19, 8:46 AM
Roche Holdings AG's (OTC: RHHBY) nine months 

RHHBF

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

Pfizer Decides To Raise COVID-19 Treatment Pill Price, Defends Itself Amid Criticism for Cost Increase

By Vandana Singh
October 19, 8:45 AM
Pfizer Inc (NYSE: PFE) is reportedly gearing up to price its Covid-19 drug Paxlovid at $1,390 for a five-day course, more than double what the U.S. government initially paid for it, at $529. 

GILD

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • News
  • Trading Ideas

Positive Outlook On Johnson & Johnson’s Partner Legend Biotech: Analyst Confident On Blood Cancer Drug

By Vandana Singh
October 18, 2:44 PM
Legend Biotech Corporation's (NASDAQ: LEGN) partner, Johnson & Johnson (NYSE: JNJ), reported Q3 Carvykti revenues of $152 million, 

JNJ

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • Equities
  • General
  • Health Care
  • Initiation
  • Markets
  • News
  • Price Target
  • Trading Ideas

Vigil Neuroscience’s Focus On Neurodegenerative Diseases: Analyst Says Pipeline Offers Upside Opportunities To Valuation

By Vandana Singh
October 18, 2:26 PM
JMP Securities has initiated coverage on Vigil Neuroscience Inc (NASDAQ: VIGL), noting the company's focus on neurodegenerative diseases.

VIGL

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Movers
  • News

Why Is AstraZeneca Stock Trading Lower Today?

By Vandana Singh
October 18, 11:57 AM
AstraZeneca Plc (NASDAQ: AZN) shares are trading lower after a data abstract on its experimental drug, datopotamab deruxtecan, for lung cancer patients in a late-stage trial disappointed some analysts.

AZN

Read More
1 minute read
  • Equities
  • General
  • Health Care
  • Markets
  • News

Amazon Unleashes Lightning-Fast Medication Delivery By Drones In College Station, Texas

By Nabaparna Bhattacharya
October 18, 11:34 AM
Amazon.Com, Inc. (NASDAQ: AMZN) has started delivering prescriptions at doorstep 

AMZN

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Movers
  • News
  • Trading Ideas

BeiGene’s Poster For Upcoming Conference Reveals Promising Lung Cancer Data

By Vandana Singh
October 18, 11:23 AM
BeiGene Ltd's (NASDAQ: BGNE) Phase 3 RATIONALE 315 study met its dual primary endpoints of major pathological response (MPR) by Blinded Independent Pathology Review (BIPR) 

BGNE

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

Bristol Myers Squibb Highlights Opdivo Regime Data In Lung Cancer Settings

By Vandana Singh
October 18, 11:15 AM
Bristol Myers Squibb & Co (NYSE: BMY) announced the first disclosure of data from the Phase 3 CheckMate -77T trial of the perioperative regimen of neoadjuvant Opdivo (nivolumab) with chemotherapy followed by surgery and adjuvant Opdivo in patients with resectable stage IIA to IIIB non-

BMY

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • News
  • Small Cap

Kura Oncology’s Head & Neck Cancer Candidate Shows Meaningful Antitumor Activity In Pretreated Patients

By Vandana Singh
October 18, 11:12 AM
Kura Oncology Inc (NASDAQ: KURA) announced results from its registration-directed AIM-HN study of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) whose disease is recurrent or metastatic (R/M) and 

KURA

Read More
1 minute read
  • Biotech
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News

Abbott Stock Gains On Q3 Performance, 10% Organic Diagnostics Revenue Growth, Raised Annual Outlook

By Vandana Singh
October 18, 9:25 AM
Abbott Laboratories (NYSE: ABT) has reported Q3 FY23 adjusted EPS of $1.14, almost similar to $1.15 a year ago, beating the con

ABT

Posts pagination

Previous 1 … 135 136 137 … 478 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service